What’s Next for Larotrectinib? - 102164


What’s Next for Larotrectinib?

Description: David Michael Hyman, MD of Memorial Sloan-Kettering talks of his hopes for LOXO-101 in future clinical practice and clinical trials at the 2017 ASCO Annual Meeting in Chicago, IL.

LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers
Shared By : AnnualMeeting2017
Posted on : 06/06/17
Added : 2 years ago
Category : Other